HIV Infection Does Not Explain Elevation of Glycated Hemoglobin among Non-Diabetic Patients in Gabon

Perret, J.-L.; Ngou-Milama, Édouard; Delaporte, Eric; Liamidi, A.; Moussavou-Kombila, Jean Baptiste; Nguemby-Mbina, C.

doi:10.1515/cclm.2000.097

Cited by 5 publications

(5 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This can occur, for example, in patients with rapid changes in glycemic control, patients with variant hemoglobins [320,322], iron-deficiency anemia [323][324][325][326], pregnancy [327][328][329], or HIV infection [330,331]. Abnormally low-HbA1c reading can be expected under conditions such as rapid loss of glycemic control [332,333], conditions that decrease erythrocyte lifespan such as hemolytic anemia [325], liver cirrhosis [334,335], hemorrhage, chronic kidney disease 249 Glycated Serum Albumin and AGE Receptors [336][337][338][339], variant hemoglobin [320,322,340], and hemoglobin in neonates [341,342].…”

Section: Glycated Hemoglobin Hba1cmentioning

confidence: 99%

Glycated Serum Albumin and AGE Receptors

Vetter

2015

Advances in Clinical Chemistry

View full text Add to dashboard Cite

Section: Glycated Hemoglobin Hba1cmentioning

confidence: 99%

Glycated Serum Albumin and AGE Receptors

Vetter

2015

Advances in Clinical Chemistry

View full text Add to dashboard Cite

“…This is the case of troubles of iron metabolism [117,118] , e.g., in HIV infection [119] even in non-diabetic subjects [120] . In all occurrences, the importance of taking into account within-subject biological variations in both type 1 [121] and type 2 [122] diabetic patients and in non-diabetic subjects [123] for clinical interpretation was underlined.…”

Section: The Times Of Expansionmentioning

confidence: 99%

A history of HbA_1c through Clinical Chemistry and Laboratory Medicine

Gillery¹

2012

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

HbA 1c was discovered in the late 1960s and its use as marker of glycemic control has gradually increased over the course of the last four decades. Recognized as the gold standard of diabetic survey, this parameter was successfully implemented in clinical practice in the 1970s and 1980s and internationally standardized in the 1990s and 2000s. The use of standardized and well-controlled methods, with well-defined performance criteria, has recently opened new directions for HbA 1c use in patient care, e.g., for diabetes diagnosis. Many reports devoted to HbA 1c have been published in Clinical Chemistry and Laboratory Medicine (CCLM) journal. This review reminds the major steps of HbA 1c history, with a special emphasis on the contribution of CCLM in this field.

show abstract

“…This low reporting partly reflects the rarity of the disease, but is likely compounded by the very low awareness of HTLV-1 and ATL among local clinicians and by the absence of diagnostic tools (point 4). Such tools are needed to establish an accurate differential diagnosis between ATL and other hematologic malignancies, including cutaneous T-cell lymphomas, such as mycosis fungoides (184,207,208) or Seźary's syndrome (133,209), which are also present in African patients. An extensive search of medical publications over a period of almost 40 years identified only about 160 reported cases of ATL in patients of African origin (Table 5).…”

Section: Htlv-1-associated Diseases 41 What Do We Know About Adult T-...mentioning

confidence: 99%

“…In Nigeria, several small series of patients with ATL hospitalized in Ibadan and Zaria have been reported, but these studies are a quite dated (3,(159)(160)(161). In Gabon, a sparsely populated country with high endemicity for HTLV-1, studies have only reported a few cases of ATL hospitalized in Libreville in the 1990s (136, 184,185). In Mali, rare cases of ATL have been diagnosed at the Institut Marchoux in Bamako (133,134), together with other cutaneous T-cell lymphomas, such as Seźary syndrome (133).…”

Section: Htlv-1-associated Diseases 41 What Do We Know About Adult T-...mentioning

confidence: 99%

Geographic distribution, clinical epidemiology and genetic diversity of the human oncogenic retrovirus HTLV-1 in Africa, the world’s largest endemic area

et al. 2023

View full text Add to dashboard Cite

The African continent is considered the largest high endemic area for the oncogenic retrovirus HTLV-1 with an estimated two to five million infected individuals. However, data on epidemiological aspects, in particular prevalence, risk factors and geographical distribution, are still very limited for many regions: on the one hand, few large-scale and representative studies have been performed and, on the other hand, many studies do not include confirmatory tests, resulting in indeterminate serological results, and a likely overestimation of HTLV-1 seroprevalence. For this review, we included the most robust studies published since 1984 on the prevalence of HTLV-1 and the two major diseases associated with this infection in people living in Africa and the Indian Ocean islands: adult T-cell leukemia (ATL) and tropical spastic paraparesis or HTLV-1-associated myelopathy (HAM/TSP). We also considered most of the book chapters and abstracts published at the 20 international conferences on HTLV and related viruses held since 1985, as well as the results of recent meta-analyses regarding the status of HTLV-1 in West and sub-Saharan Africa. Based on this bibliography, it appears that HTLV-1 distribution is very heterogeneous in Africa: The highest prevalences of HTLV-1 are reported in western, central and southern Africa, while eastern and northern Africa show lower prevalences. In highly endemic areas, the HTLV-1 prevalence in the adult population ranges from 0.3 to 3%, increases with age, and is highest among women. In rural areas of Gabon and the Democratic Republic of the Congo (DRC), HTLV-1 prevalence can reach up to 10-25% in elder women. HTLV-1-associated diseases in African patients have rarely been reported in situ on hospital wards, by local physicians. With the exception of the Republic of South Africa, DRC and Senegal, most reports on ATL and HAM/TSP in African patients have been published by European and American clinicians and involve immigrants or medical returnees to Europe (France and the UK) and the United States. There is clearly a huge underreporting of these diseases on the African continent. The genetic diversity of HTLV-1 is greatest in Africa, where six distinct genotypes (a, b, d, e, f, g) have been identified. The most frequent genotype in central Africa is genotype b. The other genotypes found in central Africa (d, e, f and g) are very rare. The vast majority of HTLV-1 strains from West and North Africa belong to genotype a, the so-called ‘Cosmopolitan’ genotype. These strains form five clades roughly reflecting the geographic origin of the infected individuals. We have recently shown that some of these clades are the result of recombination between a-WA and a-NA strains. Almost all sequences from southern Africa belong to Transcontinental a-genotype subgroup.

show abstract

HIV Infection Does Not Explain Elevation of Glycated Hemoglobin among Non-Diabetic Patients in Gabon

Cited by 5 publications

References 3 publications

Glycated Serum Albumin and AGE Receptors

Glycated Serum Albumin and AGE Receptors

A history of HbA_1c through Clinical Chemistry and Laboratory Medicine

Geographic distribution, clinical epidemiology and genetic diversity of the human oncogenic retrovirus HTLV-1 in Africa, the world’s largest endemic area

Contact Info

Product

Resources

About

HIV Infection Does Not Explain Elevation of Glycated Hemoglobin among Non-Diabetic Patients in Gabon

Cited by 5 publications

References 3 publications

Glycated Serum Albumin and AGE Receptors

Glycated Serum Albumin and AGE Receptors

A history of HbA1c through Clinical Chemistry and Laboratory Medicine

Geographic distribution, clinical epidemiology and genetic diversity of the human oncogenic retrovirus HTLV-1 in Africa, the world’s largest endemic area

Contact Info

Product

Resources

About

A history of HbA_1c through Clinical Chemistry and Laboratory Medicine